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Summary
The molecular basis governing functional behavior of
human hematopoietic stem cells (HSCs) is largely un-
known. Here, using in vitro and in vivo assays, we
isolate and define progenitors versus repopulating
HSCs from multiple stages of human development for
global gene expression profiling. Accounting for both
the hierarchical relationship between repopulating
cells and their progenitors, and the enhanced HSC
function unique to early stages of ontogeny, the hu-
man homologs of Hairy Enhancer of Split-1 (HES-1)
and Hepatocyte Leukemia Factor (HLF) were iden-
tified as candidate regulators of HSCs. Transgenic hu-
man hematopoietic cells expressing HES-1 or HLF
demonstrated enhanced in vivo reconstitution ability
that correlated to increased cycling frequency and in-
hibition of apoptosis, respectively. Our report identi-
fies regulatory factors involved in HSC function that
elicit their effect through independent systems, sug-
gesting that a unique orchestration of pathways fun-
damental to all human cells is capable of controlling
stem cell behavior.
Introduction
Rare hematopoietic stem cells (HSCs) are responsible
for production and maintenance of mature human
blood cells (Morrison et al., 1995). HSCs are defined by
two functional properties: vast proliferative self-renewal
ability, and multilineage hematopoietic differentiation
potential (Morrison et al., 1995). In the human, cellular
characteristics of primitive hematopoietic cells and pu-
tative HSCs can only be experimentally investigated by
using surrogate approaches (Dick, 1996). In vitro pro-
genitor assays are widely used to measure primitive
colony-forming unit (CFU) (Sutherland et al., 1989) ac-
tivity, but this assay is not indicative of stem cell func-
tion since it is short term and limited to myeloid progen-
itor detection. Only in vivo xeno-transplantation assays
(Dick, 1996) are able to assess the multilineage differen-
tiation and proliferative self-renewing properties that*Correspondence: mbhatia@robarts.cadefine HSCs (Enver et al., 1998). Since transplantable
HSCs can give rise to progenitors detected in vitro,
whereas in vitro progenitors lack multilineage repopu-
lating function in vivo, a hierarchical arrangement of
hematopoietic cells can be assembled based on these
functional assays in which repopulating HSCs are posi-
tioned at the apex, followed by more abundant progeni-
tors with more restricted proliferative and develop-
mental potential (Orkin and Zon, 2002; Verfaillie, 2002).
In addition to the functional relationships that define
progenitors and HSCs, the ontogenic origin of mamma-
lian HSCs is also related to changes in overall HSC ca-
pacity (Geiger and Van Zant, 2002). Both proliferative
ability and differentiative potential of HSCs decline with
age, e.g., HSCs obtained from the fetus possess
greater proliferative and differentiative capacity than
those isolated from adult mice (Geiger and Van Zant,
2002). Since hematopoietic function must be sustained
for the lifetime of an organism and is therefore depen-
dent on HSCs, rigid control of HSC survival and differ-
entiation decisions throughout the aging and develop-
ment process is critical (Geiger and Van Zant, 2002;
Verfaillie, 2002). Despite these biological observations
and collective functional understanding of mammalian
HSCs, the molecular mechanisms that tightly regulate
HSC physiology (Murdoch et al., 2001; Orschell-Tray-
coff et al., 2000; Domen et al., 2000) and cell fate remain
poorly understood (Lemischka, 1999). In the current
study, we use in vitro and in vivo assays, combined with
prospective isolation of cell populations defined to pos-
sess properties of either progenitors or repopulating
HSCs from multiple stages of human development, for
global gene expression profiling. We reveal two regula-
tory transcription factors involved in human HSC func-
tion that elicit their effect through independent mecha-
nisms capable of controlling stem cell behavior in vivo.
Results
Functional Characterization and Isolation of Human
Hematopoietic Progenitors and Repopulating Stem
Cells during Human Development
Based on our current knowledge of human HSC char-
acteristics, molecular profiling that discriminates genes
expressed in HSCs from those expressed in more ma-
ture progenitors (hierarchical) and those genes that dis-
tinguish functionally unique HSCs at different stages of
mammalian development (ontogenic) should be taken
into account to best define the molecular basis of HSC
behavior. Using this premise, subsets of lineage-
depleted (Lin−) human hematopoietic cells with multi-
lineage repopulating capacity (Lin−CD34+CD38−), and
Lin− hematopoietic cells capable of in vitro progenitor
function but devoid of in vivo repopulating ability
unique to HSCs (Lin−CD34+CD38+), were isolated.
Lin−CD34+CD38− and Lin−CD34+CD38+ were purified
from Lin− fractions of human fetal blood (FB), cord
blood (CB), and mobilized peripheral blood (MPB) with
more than 99% purity upon reanalysis (Figure 1A). Al-
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652Figure 1. Functional Characterization of Purified Human FB, CB, and MPB Hematopoietic Subsets with In Vitro and In Vivo Assays
(A) Isolation of Lin−CD34+CD38− and Lin−CD34+CD38+ populations from FB, CB, BM (not shown), and MPB. Lin− from the above-mentioned
populations (biological and experimental replicates from each preparation are detailed in Table S1) were enriched and stained with anti-
CD34-APC and anti-CD38-PE and were sorted according to the sorting gates assigned for CD34+CD38− (I) and CD34+CD38+ (III) populations.
Reanalysis of sorted fractions (II and IV) verified purity of the populations of interest from each stage of ontogeny.
(B) CFU capacity: 1200 cells from each population were plated in methyl cellulose supplemented with SCF, GM-CSF, IL-3, and EPO, followed
by total colony counts after 14 days of incubation at 37°C.
(C) Repopulating capacity: cells from each population were intravenously transplanted into NOD/SCID mice at a range of 5,000–10,000
Lin−CD34+CD38− cells, and from 10,000 to 200,000 Lin−CD34+CD38+ cells from all human ontogenic sources indicated. Human engraftment
was evaluated 6 weeks posttransplant by staining cells harvested from BM of transplanted mice with monoclonal antibody against human
CD45. The level of engraftment represents the percentage of human hematopoietic chimerism in the BM for recipient mice. (“**” and “*,”
statistically different, p < 0.05).
(D) BM cells of transplanted animals were stained with several cell surface markers to examine the percentage of myeloid (CD33, CD15),
lymphoid (CD19, CD20), and primitive (CD34, CD38) cells indicative of multilineage human hematopoietic engraftment. Averages and SEM
for each subset are provided in quadrants based on 4–8 independent experiments for FB, CB, and MPB repopulating HSCs respectively,
n = 18.
(E) The subsets indicated were stained with Ki67-FITC antibody as per the protocol (see Experimental Procedures) and analyzed by flow
cytometry. “*,” statistically different, p < 0.01.
(F) Proposed model to account for hierarchical and ontogenic position of human HSCs and nonrepopulating progenitors.
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human hematopoietic ontogeny (since primitive cells
are induced to the circulation via cytokine administra-
tion), MPB represents an established and accessible
source of adult HSCs for fundamental investigation.
Within each stage of ontogeny (fetal, neonatal, and
adult), clonogenic progenitor capacity measured by the
in vitro CFU assay (Sutherland et al., 1990) was similar
between Lin−CD34+CD38− and Lin−CD34+CD38+ cells,
with adult MPB sources possessing far less clonogenic
progenitor capacity, independent of the population iso-
lated (Figure 1B). However, in vivo functional analysis
by intravenous (IV) transplantation into immune-defi-
cient recipient NOD/SCID mice demonstrated that only
Lin−CD34+CD38− from human FB, CB, and MPB pos-
sessed repopulating ability (Figure 1C). Therefore, these
purified populations represent a hierarchical distinction
within the human hematopoietic system in which
Lin−CD34+CD38− repopulating cells include functional
human HSCs (termed “repopulating cells” herein) and
Lin−CD34+CD38+ are restricted to the progenitor com-
partment (termed “nonrepopulating progenitors” herein).
This hierarchical relationship was conserved at all
stages of human ontogeny, indicating that the pheno-
type used to define putative human HSCs and re-
stricted progenitors is reliable and provides a useful
means to distinguish these subsets throughout human
development.
In addition to the consistency of HSC and progenitor
function within these two subsets, detailed analysis of
engrafted animals indicated a gradual decline in human
HSC repopulating ability from FB to CB to MPB, where
both the level and frequency of human engraftment in
FB was greater than CB and, in turn, greater than MPB
(Figure 1C). Furthermore, the level and frequency of re-
populating capacity are higher in FB HSCs versus CB
and MPB HSCs, and, in turn, CB HSC capacity is higher
than that of MPB HSCs (Figure 1C). Other than a pro-
pensity for more myeloid versus lymphoid differentia-
tion arising from reconstituting FB HSCs, all sources
of human HSCs possessed multilineage differentiation
capacity in vivo (Figure 1D). The gradual reduction of
reconstitution capacity from FB to CB to adult MPB
HSCs prompted us to examine cell cycle status (Glimm
et al., 2000) of Lin−CD34+CD38− cells and Lin−CD34+
CD38+ progenitors from all stages of human ontogeny
by using Ki67 staining (Glimm et al., 2000) (Figure 1E).
Higher cycling activity in all nonrepopulating progeni-
tors compared to repopulating cells confirmed the
unique quiescent state associated with de novo iso-
lated HSCs (Srour et al., 2001; Murdoch et al., 2001).
However, consistent with reconstituting capacity (Fig-
ure 1C), FB Lin−CD34+CD38− cells demonstrated greater
cycling activity compared to similar cells from CB and
MPB (p < 0.05, Figure 1E). Collectively, these data re-
veal that differences between repopulating capacity of
HSCs isolated from different stages of human ontogeny
correlate with differences in cell cycle activity that are
likely to affect the in vivo proliferative capacity of HSCs.
Despite the fact that the HSCs have similar cell sur-
face phenotypes and functional properties at various
stages of human development, our results demonstrate
an ontogenic distinction of human repopulating HSCs,
but not of more mature progenitors: ontogenically earlyHSCs possess superior proliferative and self-renewal
capacity compared to their aged counterparts. Based
on our functional observations, we suggest a model to
position human HSCs that accounts for both hierarchi-
cal and ontogenic characteristics of the primitive
hematopoietic compartment in the human (Figure 1F).
This model illustrates that human HSCs versus progeni-
tors are restricted to a specific population of hemato-
poietic cells throughout life, suggesting that the hierar-
chical arrangement of the hematopoietic system is
conserved during development, but also accounts for
higher proliferative potential of fetal HSCs, and the
gradual decline in this property within human HSCs to-
ward adult life. We suggest that the gene expression
profiles that regulate functional capacity of human
HSCs are more abundantly expressed in FB HSCs ver-
sus neonatal and adult sources, and that these profiles
are restricted to HSCs versus progenitors at all stages
of human development.
Molecular Profiling of Purified Cells Comprising
the Human Hematopoietic Hierarchy
throughout Human Ontogeny
Utilizing the conserved hierarchical relationship be-
tween repopulating HSCs and nonrepopulating progen-
itors, and the ontogenic relationships among human
HSCs functionally defined and modeled in Figures 1A–
1F, we established a strategy to define the molecular
basis of human HSC behavior through global gene ex-
pression analysis of purified subsets by using microar-
ray. To provide an in depth assessment, several experi-
mental and biological replicates were used (Table S1,
see the Supplemental Data available with this article
online). To simultaneously account for hierarchy and
ontogenic positioning of HSCs, our strategy for molec-
ular analysis used several filters (Figure 2A). First, we
applied hierarchical discrimination that identified all
genes expressed in repopulating Lin−CD34+CD38−
fractions of FB, CB, bone marrow (BM), and MPB that
were differentially expressed from nonrepopulating pro-
genitors at each stage of ontogeny. Adult BM was
added in these analyses to provide an additional
source of adult HSCs. This filter provided genes
uniquely enriched in repopulating human HSCs at all
stages of human development and included 366 and
329 genes up- and downregulated, respectively (Tables
S3 and S4). Self-organizing map (SOM) (Tamayo et al.,
1999) clustering provided correlative nodes of dif-
ferentially expressed genes identified (Figure S1). In the
second filter, ontogenic discrimination was applied to
identify HSC-enriched transcripts that were preferen-
tially expressed in early versus later stages of human
development (Figure 2A). Third, we further selected
genes based on the hypothesis that transcription
factors are likely to play a substantive role in HSC regu-
lation (Ramalho-Santos et al., 2002). This bioinformat-
ics strategy, unique to human hematopoietic cell mo-
lecular profiling, resulted in the identification of 16
candidate transcription factors (Figure 2B), of which
STAT-1 (Jenkins et al., 2002), Id3 (Cooper et al., 1997),
Ets1 (Dieterlen-Lievre et al., 1993), HLF (Crable and An-
derson, 2003), and HES-1 (Kunisato et al., 2003) have
been previously implicated in primitive hematopoiesis.
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Figure 2. Identification of Candidate Transcription Factors Regulating Human HSCs with a Unique Strategy Based on Hierarchical and Onto-
genic Positioning
(A) Using global gene expression analysis of human Lin−CD34+CD38− from FB, CB, BM, and MPB and Lin−CD34+CD38+ progenitors,
transcripts were interrogated by microarray analysis. Bioinformatics-based priority filters were applied as schematically illustrated and in-
cluded hierarchical and ontogenic discrimination, followed by the selection of candidate DNA binding transcription factors.
(B) A total of 16 transcripts were identified by using the strategy shown in (A). A complete list of differentially regulated genes is available as
Table S3. Abbreviations: POLD4, polymerase delta4; TEF4, transcriptional enhancer factor4; HES-1, hairy enhancer of split; LIM, zinc binding
domain present in Lin-11, Isl-1, Mec-3; HLF, hepatic leukemia factor; PAX8, paired box gene8; Id3, inhibitor of DNA binding3; HOXA6,
homeobox A6; ETS1, erythroblastosis virus E26 oncogene homolog 1; STAT1, signal transducer and activator of transcription; ZNFP1&2, zinc
finger protein; EST, expressed sequenced tag; MBLL, melanogaster muscle Blind B; PHRET1, PH domain containing protein in retina 1.
(C) Expression profile of HES-1 and HLF in freshly isolated Lin−CD34+CD38− cells derived from all stages of human ontogeny using
Q-RT-PCR.
(D and E) Q-RT-PCR was used to analyze the ratio of (D) HES-1 and (E) HLF expression in Lin−CD34+CD38− to Lin−CD34+CD38+ from FB,
CB, and MPB sources. All Q-RT-PCR analysis was normalized to GAPDH transcript, and differential expression was calculated by using the
Ct equation. “*,” statistically different than corresponding expression in Lin−CD34+CD38+ cells, p < 0.05.
(F) Full-length cDNA of HES-1 was cloned in the EcoRI and XhoI sites, and HLF full-length cDNA was cloned in the EcoRI and SalI sites of
the MIEV retrovirus vector as illustrated.
(G) Schematic illustration of experimental design to functionally analyze the effect of HES1 and HLF overexpression by using retroviral
gene reconstitution.
(H) Lineage-depleted population from human CB was transduced with viral supernatant containing HES-1, HLF, and vector alone. Gene
transfer efficiency was determined by the percentage of GFP+ cells 6 days posttransduction by using flow cytometry and primitive hematopoi-
etic phenotype using CD34 expression.
(I and J) Summary of the total number of (I) GFP+ and (J) CD34+GFP+ transgenic cells 6 days posttransduction.Identification of HES-1 and HLF as Candidate
Regulators of Human Hematopoietic
Repopulating Stem Cells
Of the 16 candidates identified (Figure 2B), HES-1 and
HLF expression best mirrored the functional model we
predicted to be the most relevant to overall HSC beha-
vior (Figure 1F). Quantitative real-time PCR (Q-RT-PCR)
using freshly isolated FB, CB, and adult BM and MPB
Lin−CD34+CD38− cells demonstrated a declining pat-
tern of expression from FB to neonatal to adult sources
(Figure 2C). In addition, the ratio of HES-1 and HLF ex-
pression between Lin−CD34+CD38− repopulating cells
and Lin−CD34+CD38+ progenitors was consistently
greater than 1 (i.e., HSC expression > progenitor ex-
pression) at all stages of ontogeny, and this ratio declined
from early to late stages of HSC/progenitor development
(Figures 2D and 2E). This pattern of expression was
unique to HES-1 and HLF-1 in comparison to other
genes examined in a similar manner (data not shown).
Accordingly, HES-1 and HLF were selected for further
functional analysis.
HES-1 is a basic-helix-loop-helix transcriptional re-
pressor that inhibits differentiation of many cell types
(Ishibashi et al., 1994; Kageyama et al., 2000; Nakamura
et al., 2000) and is a downstream target of the Notch
signaling pathway (Karanu et al., 2000b, 2001, 2003;
Kumano et al., 2003; Varnum-Finney et al., 2000). A re-
cent study has shown that HES-1 is able to maintain
the reconstitution ability of mouse CD34−Lin−c-Kit+
Sca-1+ HSCs (Kunisato et al., 2003). HLF is closely re-
lated to zipper-containing transcription factors that
have a role in developmental stage-specific gene ex-
pression (Inaba et al., 1992), and it has recently been
shown to activate the LMO2 promoter (Crable and An-
derson, 2003) necessary for initiation of mammalian
embryonic hematopoiesis (Warren et al., 1994). In addi-
tion, HLF was found to be involved in acute human leu-
kemias when fused to the E2A basic-helix-loop-helix
transcription factor (Honda et al., 1999; Inaba et al.,profiling studies (Georgantas et al., 2004; Ivanova et al.,
2002). To functionally examine a potential role of HES-1
and HLF in human HSCs, full-length cDNA coding se-
quences for each gene were subcloned into a retroviral
vector under the control of a constitutively active pro-
moter and upstream of the reporter gene-enhanced
green fluorescent protein (GFP) (Figure 2F). Human CB
Lin− cells containing both CD34+CD38− and CD34+
CD38+ subsets were used to evaluate the role of HES-1
and HLF based on subsequent functional readout of
repopulating HSCs and nonrepopulating progenitors
overexpressing the transduced gene. Following trans-
duction of primary human Lin− CB cells, the in vitro
proliferative capacity, phenotype, progenitor potential,
and in vivo repopulating function of HES-1 and HLF
transgenic human hematopoietic cells were compared
to vector-transduced controls. Our experimental strat-
egy is illustrated in Figure 2G. HES-1, HLF, and vector
alone retrovirally transduced hematopoietic cells were
analyzed by flow cytometry for GFP and cell surface
CD34 expression (Figure 2H). No difference in retroviral
transduction (number of GFP+ cells, Figure 2I) or total
number of primitive CD34+ cells was detectable (Figure
2J). These transgenic human cells overexpressing HES-1
and HLF were used in functional in vitro and in vivo
assays to evaluate the affects of these genes on pro-
genitor and HSC behavior, respectively.
HES-1 and HLF Augment Human Hematopoietic
Stem Cell Activity In Vivo
Transduction of HES-1 or HLF had no effect on in vitro-
detected progenitors, suggesting that overexpression
of these genes does not impact functional properties
of nonrepopulating cells. Transduced (GFP+) hemato-
poietic progenitor frequency or lineage composition
were not affected by overexpression of the HES-1 or
HLF transgene (Figures 3A and 3B) since erythroid,
macrophage, and granulocytic CFU subtypes were
equally identified.
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(A) Number of clonogenic progenitors transduced with HES-1 (blue bars), HLF (yellow bars), and vector (black bars) by using the CFU assay.
A total of 1000 transgenic (GFP+ sorted) cells were plated into methylcellulose supplemented with SCF, GM-CSF, IL-3, and EPO, and dif-
ferential colony counts of CFU subtypes (erythroid, macrophage, and granulocyte) were determined and compared after 14 days.
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(B) Representative examples HES-1, HLF, and vector alone transgenic progenitors detected in the CFU assay confirming transgene expression
in multiple hematopoietic lineages.
(C) Comparison of multilineage human hematopoietic reconstitution from HES-1, HLF, and vector transgenic repopulating HSCs in the BM of
transplanted mice. Approximately equal numbers of transgenic (GFP+) cells (average of 75,000) were transplanted in each mouse by using a
total of seven independent human CB samples, n = 35. Mouse BM was stained with anti-CD45-APC (to identify human cells); anti-CD10 and
anti-CD19-PE (to identify B lymphoid lineage), anti-CD13, -CD14, -CD15, and -CD33-PE (to identify myeloid lineage); and anti-CD34 (to identify
primitive human hematopoietic component) antibodies and analyzed by flow cytometry 6 weeks posttransplantation of human cells.
(D) The level of human hematopoietic repopulating capacity was compared as a percentage of human GFP+ transgenic cells, and the
frequency of engrafted mice intravenously transplanted with transgenic HES-1-, HLF-, and vector alone-transduced cells 6 weeks after
transplantation is shown. “*,” the average level of engraftment is statistically different from the level of repopulation in mice transplanted with
vector-transduced HSCs, p < 0.05.
(E) Frequency of transgenic cells expressing cell surface molecules CD44, CD49, and CXCR4 associated with HSC homing to the bone
marrow compartment.
(F) The average level of human hematopoietic repopulation (inset) from HES-1, HLF, and vector alone transgenic HSCs delivered directly to
the recipient bone marrow site by intrafemoral bone marrow transplantation (IBMT), n = 9. “*,” the average level of engraftment is statistically
different from the level of repopulation in mice transplanted with vector-transduced HSCs, p < 0.05.duced cells were intravenously transplanted into recipi-
ent NOD/SCID mice to investigate the in vivo effect of
these genes on repopulating human HSCs. Multilineage
human reconstitution of HES-1 and HLF transgenic hu-
man HSCs did not differ from vector-transduced repop-
ulating cells, and both lymphoid and myeloid lineages,
along with primitive subpopulations of CD34+ cells,
were detectable at similar frequencies in engrafted re-
cipients (Figure 3C). This suggests that HES-1 and HLF
do not affect lineage differentiation of human HSCs.
However, mice transplanted with HES-1 or HLF trans-
genic HSCs revealed a dramatic increase in the level of
BM reconstitution and number of HSCs, as indicated
by increased frequency of engrafted recipients, n = 35
(Figure 3D). Based on the levels of human chimerism,
human HSC capacity was enhanced by w6-fold upon
overexpression of HES-1 and w4-fold upon overex-
pression of HLF compared to vector-transduced HSCs
(Figure 3G). Therefore, despite the lack of effect on pro-
genitor capacity, HSC repopulation potential was dra-
matically enhanced in transgenic cells overexpressing
HES-1 or HLF. These functional analyses validate our
original strategy to identify key molecular regulators of
HSC behavior in vivo that are distinct from regulators
of nonrepopulating hematopoietic progenitors.
Since HSC capacity was evaluated in vivo by IV
transplantation, increased repopulating capacity of
transgenic HES-1 and HLF human HSCs may be due to
enhanced ability to home to the recipient bone marrow
compartment. Cell surface expression of proteins asso-
ciated with increased homing capacity, CD44, CD49,
and CXCR4, were equally expressed on HES-1-, HLF-,
and vector-transduced cells (Figure 3E). To functionally
evaluate the effect of HES-1 and HLF on homing ability
of HSCs, human cells overexpressing HES-1 and HLF
were seeded directly into the femoral bone marrow
space of recipient mice by using intrafemoral bone
marrow transplantation (IBMT) (Mazurier et al., 2003a).
HSC capacity of transgenic cells delivered by IBMT
was compared to HSCs transduced with vector alone.
Similar to results observed after IV transplantation (Fig-
ure 3D), IBMT of transgenic HSCs demonstrated that
human HSC activity was equally enhanced by overex-
pression of HES-1 and HLF, n = 9 (Figure 3F). These
results indicate that HES-1 and HLF do not likely affect
homing capacity of human HSCs, and prompted eluci-HES-1 and HLF Act Independently to Enhance Cell
Cycle and Inhibit Apoptosis of Human
Hematopoietic Stem Cells, Respectively
Based on the robust effect of HES-1 and HLF in en-
hancing human HSC function independent of HSC-
specific homing properties to the bone marrow in trans-
planted recipients, we sought to understand the
underlying mechanism involved through the consider-
ation of fundamental pathways that impact all human
cell types, such as cell cycle and apoptotic status. Brd-U
incorporation and 7-AAD staining of transgenic cells
were used to determine the cell cycle status by analyz-
ing the frequency of primitive CD34+ dormant (G0–G1)
and cycling (S and G2+M) cells (Figure 4A). While HLF
transgenic and vector control cells were similar to each
other with respect to distribution among the different
stages of the cell cycle, a greater proportion of HES-1
transgenic cells was actively cycling, and a corre-
spondingly smaller proportion was found to be quies-
cent (Figure 4B). Based on these observations, we
sought to evaluate the affect of HES-1 on cell cycle
activity on transgenic human HSCs compared to HLF-
and vector-transduced cells in vivo by Brd-U labeling.
Brd-U is passively taken up by cells and stably incorpo-
rated into the DNA of cells undergoing mitotic division,
thereby providing a retrospective method to evaluate
actively dividing parent cells that give rise to Brd-U+
progeny. Recipient mice were transplanted with human
HSCs overexpressing HES-1 or HLF and were adminis-
tered Brd-U for 3 days prior to sacrifice between 5–6
weeks posttransplantation. Our experimental design is
illustrated in Figure 4C. Mice transplanted with trans-
genic human HES-1 cells demonstrated a larger num-
ber of primitive CD34+ cells incorporating Brd-U as
compared to either HLF- or vector-transduced repopu-
lating HSCs (Figure 4D). These data indicate that HES-1
is able to augment proliferative capacity of transgenic
human HSCs in vivo, whereas HLF overexpression had
no influence on cell cycle status of human HSCs.
While HES-1 overexpression increases cycling of
primitive cells, HLF transgenic cells had a similar cell
cycling status profile to vector-transduced cells, sug-
gesting that HLF confers enhanced repopulation ca-
pacity on human HSCs via an alternative mechanism
(Figures 4A–4E). Given previous observations of the
ability of HLF to inhibit apoptosis (Hitzler et al., 1999),
Developmental Cell
658Figure 4. Characterization of Cell Cycle and Apoptosis Regulation in HES-1-, HLF-, and Vector-Transduced Primary Human Hematopoietic
Cells
(A) Human CB CD34+ cells transduced with HES-1, HLF, and vector alone were pulsed with Brd-U for 2 hr, followed by fixation and washing,
and were stained with anti-Brd-U-APC and 7-AAD to analyze the fraction of cells at different stages of the cell cycle, including G0+G1, S,
and G2+M phases.
(B) Quantitative summary of cycling and noncycling HES-1 (blue bars), HLF (yellow bars), and vector alone (black bars) transgenic cells. “*,”
statistically different from HLF- and vector-transduced cells, p < 0.05.
(C) Schematic illustration of the experimental design used to evaluate mitotically active cells repopulating recipient mice.
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(D and E) (D) Representative analysis and (E) summary of human hematopoietic cells repopulating the bone marrow of recipient NOD/SCID
that have incorporated Brd-U after in vivo administration. “*,” statistically different from HLF- and vector-transduced cells, p < 0.05.
(F and G) (F) HES-1-, HLF-, and vector-transduced CD34+ cells were fixed and stained with Annexin-V-APC, and the percentage of preapo-
ptotic cells is summarized in (G) and expressed as the percentage of apoptotic cells relative to vector control-transduced cells. “*,” statistically
different from HES-1- and vector-transduced cells, p < 0.05.
(H and I) (H) Representative Q-RT-PCR of BCL-2, SODD, and TOSO expression in human hematopoietic cells transduced with HES-1, HLF, or
vector alone as indicated, and the (I) average level of gene expression summarized. GAPDH was used as a housekeeping control to normalize
cDNA input. The average level of gene expression was based on the results of four independent experiments. “*,” the BCL-2 gene expression
level is statistically different from that in HES-1- and vector-transduced cells, p < 0.05.cells. Annexin-V staining for preapoptotic cells (Figure
4F) revealed a significantly smaller Annexin-V+ popula-
tion in HLF transgenic CD34+ cells compared to either
HES-1- or vector control-transduced CD34+ cells (Fig-
ure 4G), suggesting that HLF transgenic cells are less
prone to apoptotic cell death. Since mechanisms and
targets of apoptotic control are species and cell
context specific (Danial and Korsmeyer, 2004), we
aimed to further characterize the potential target genes
associated with apoptotic control via HLF that specifi-
cally affect human hematopoietic cells. Within the
context of hematopoietic cells, SODD (Takada et al.,
2003), TOSO (Song and Jacob, 2005), and Bcl-2 (Cory
et al., 2003) have been identified as factors controlling
apoptosis. Accordingly, primitive human hematopoietic
cells transduced with HES-1 or HLF were isolated and
examined quantitatively for changes in SODD, TOSO,
and Bcl-2 expression compared to vector-transduced
cells (representative Q-RT-PCR analysis, Figure 4H).
Our results demonstrate that overexpression of HLF in
primitive human hematopoieitc cells induces Bcl-2 ex-
pression, but has no effect on the levels of either SODD
or TOSO (Figure 4I). In contrast, cells’ overexpression
of HES-1 did not alter Bcl-2, SODD, or TOSO levels,
providing further evidence of the inability of HES-1, as
compared to HLF, to influence apoptosis of transgenic
cells (Figure 4I). We suggest that HLF targets antiapo-
ptotic pathways associated with complex Bcl-2 regula-
tion in human HSCs, similar to effects observed by
using Bcl-2 mutations in mouse HSCs (Domen et al.,
2000). Taken together, our results reveal that HES-1 and
HLF promote cell cycling and reduce apoptosis,
respectively, thereby enhancing repopulating capacity
of human HSCs via independent pathways.
To characterize HES-1 and HLF gene targets, and to
further investigate potential downstream signaling of
these two transcriptional regulators, transgenic cells
were isolated and analyzed by Q-RT-PCR. As would be
predicted, HES-1- and HLF-transduced cells demon-
strated a 20- and 27-fold greater level of HES-1 and
HLF expression, respectively, compared to vector-
transduced cells (Figure 5A). Consistent with their ob-
served independent mechanisms of action, neither
HES-1 nor HLF affected the expression of the other
(Figure 5A), suggesting limited overlap between their
respective pathways. Similar to other studies (Ronchini
and Capobianco, 2001), HES-1 upregulated expression
of CDK-2 but had no effect on a recently identified pu-
tative target gene of HLF, LMO2 (Crable and Anderson,
2003). Conversely, HLF upregulation increased LMO2
expression (Figure 5A) but had no effect on CDK-2 ex-
pression. The distinct roles of HES-1 and HLF are fur-
ther supported by the distinct clustering location ofSeveral candidate regulators of human stem cell fate
have also been implicated or originally identified from
human cancers. As such, transformation events and
pathways influenced by transformation may be related
to the regulators of human HSCs (Pardal et al., 2003).
Genetic rearrangement of HLF with E2A has been ob-
served in human leukemias and associated with re-
duced apoptosis in leukemic progenitors (Kurosawa et
al., 1999). Using PCR amplification, we were unable to
detect HLF-E2A transcripts in primary HLF-transduced
cells (Figure 5B), indicating that our observation of HLF
apoptotic inhibition is independent of primary human
cells harboring HLF-E2A mutations. Similarly, the Notch
pathway has been implicated in human leukemias, and
it has been shown in nonhuman systems to affect HES-1
expression. To evaluate whether HES-1 could be
targeted for regulation, human HSCs were purified and
treated with Jagged-1 (Karanu et al., 2000b). Short-
term stimulation of purified cells with Jagged-1 demon-
strated an increase in HES-1 expression within 24 hr,
compared to protein control (IgG)-treated cells (Figure
5C). Upregulation of HES-1 could be sustained by 72
hr, but it required the addition of Jagged-1 (Figure 5C),
suggesting that HES-1 could be upregulated but re-
quires continual stimulation similar to that achieved by
overexpression of HES-1 in transgenic HSCs regulated
by retroviral vectors. We suggest that HES-1 and HLF
enhance the reconstitution capacity of human HSCs
through independent systems, and that pathways gov-
erning fundamental cell physiology, which include cell
cycle regulation and apoptotic control, are capable of
modulating human HSC function.
Discussion
The molecular basis that defines human HSCs has
been under intensive investigation (Georgantas et al.,
2004; Ivanova et al., 2002; Ramalho-Santos et al., 2002;
Steidl et al., 2002), but few insights into complex HSC
behavior have emerged. The frequency of repopulating
HSCs or progenitors enriched in all sources of human
Lin−CD34+CD38− and Lin−CD34+CD38+ cells sug-
gests that the vast majority of cells within these popula-
tions are in fact not HSCs or progenitors, and therefore
these purified subsets represent extremely hetero-
geneous populations not likely suitable for molecular
profiling (Iscove et al., 2002). Despite these concerns,
our unique strategy allowed for identification of two
candidates’ genes capable of regulating repopulating
HSCs and not progenitors, demonstrating the impor-
tance of these genes in functional features used to de-
fine HSCs enriched in the Lin−CD34+CD38− popula-
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(A) Q-RT-PCR of HES-1, HLF, CDK-2, and LMO2 genes with cDNA from primary human hematopoietic cells transduced with HES-1 or HLF as
indicated. “*,” statistically different, p < 0.05.
(B) Conventional PCR of cDNA. Lanes: 1, molecular marker; lanes 2, 3, and 4, primary human CB cells transduced with HLF; lane 5, positive
control using diagnosed human acute lymphoblastic leukemia sample containing HLF-E2A rearrangement; lane 6, No-RT control.
(C) Regulation of HES-1 in purified Lin−CD34+CD38− cells evaluated by Q-RT-PCR in response to Jagged-1 treatment at 24 and 72 hr as
compared to control-treated cells. “*,” statistically different, p < 0.05.assays used to determine the frequency of human re- c
tpopulating cells in purified subsets underestimate HSC
content, and/or these purified populations are more g
tmolecularly homogeneous than originally predicted.
Since our study identifies two candidate genes that u
rmodulate the repopulation capacity of human HSCs,
our unique strategy that accounts for both hierarchical a
dand ontogenic positioning of human HSCs themselves
may have enabled these findings. By first defining hu- i
dman HSCs and progenitors via prospective purification
and use of established functional assays, our approach t
sto classify genes involved in HSC regulation could be
tested via gene reconstitution of identified candidates H
Hby using the same functional criteria of HSC repopula-
tion on which the study was founded. We believe that m
oour report represents a demonstration of the power of
molecular profiling when based on functional criteria n
gand biological outcomes.
Identification of HES-1 as one of the upregulated a
Htranscripts in both hierarchical and ontogenic compari-
sons underscores the role of the Notch pathway in hu- i
tman HSC regulation (Karanu et al., 2000b; 2001, 2003;
Ohishi et al., 2002; Varnum-Finney et al., 2000). Al- a
tthough the importance of Notch signaling to HSCs was
previously appreciated, details of the cellular mecha- b
lnism were unknown. Our current report provides inde-
pendent evidence for HES-1 as a putative Notch target rapable of regulating human HSC capacity via modula-
ion of the cell cycle involving upregulation of CDK-2
ene expression. Unexpectedly, our analysis also iden-
ified the DNA binding transcription factor HLF as a
niquely associated factor involved in maintaining the
epopulating capacity of human HSCs by conferring
ntiapoptotic effects and preventing premature cell
eath that are mediated in part by Bcl-2 regulation. The
dea that HES-1 and HLF impact HSC function via two
ifferent mechanisms, and that these mechanisms act
hrough fundamental pathways (cell cycle and apopto-
is) common to all human cells, suggests that specific
SC genes may not molecularly define the basis of
SC behavior. Alternatively, a unique combination of
ore general signaling pathways active in the majority
f specialized cell types may define the molecular sig-
ature of human stem cells (Pyle et al., 2004) (e.g.,
enes required to establish HSCs during development
re not required to sustain or molecularly define HSCs).
owever, independent categories that delineate signal-
ng pathways and transcription factors that are “essen-
ial” versus those that “augment” existing HSC function
re emerging. These categories may be related, but
hey may allow access to unique components of HSC
ehavior. Those that fall in the category of essential are
ikely to disrupt HSC function upon inactivation and, as
ecent studies indicate, do not seemingly include Jag-
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or β-catenin based signaling induced by Wnt pathway
activation (Cobas et al., 2004). Despite these observa-
tions, both Notch (Karanu et al., 2000a; Varnum-Finney
et al., 2000) and Wnt signaling (Murdoch et al., 2003;
Reya et al., 2003) have been identified to expand or
augment baseline HSC function.
Based on the fundamental role of human HSC regu-
lating genes identified here, the search for genes that
delineate “stemness” (Ivanova et al., 2002; Ramalho-
Santos et al., 2002) may amount to diminutive changes
in gene expression effecting universal signaling path-
ways that synergize to influence functional properties
that define tissue-specific stem cells once they have
developed in utero. Whether global gene analysis will
aid in providing new insights into the concept of stem-
ness or in identifying all of the genes that impact stem
cell behavior remains to be determined.
Experimental Procedures
Human Cell Purification
Samples of human fetal blood (FB) from early gestation (16–22
weeks), CB from the umbilical vein of neonates, BM from the iliac
crest of healthy donors, and peripheral blood mobilized by granulo-
cyte colony-stimulating factor (G-CSF) were obtained in conjunc-
tion with local ethical and biohazard authorities of the University of
Western Ontario and London Health Sciences Center. Samples
were diluted (1:4) with α-minimal essential medium (GIBCO-BRL,
Grand Island, NY) or PBS, and mononuclear cells (MNCs) were iso-
lated by using Ficoll-Paque (Pharmacia) centrifugation (Gallacher
et al., 2000). Subsets of Lin−CD34+CD38− and Lin−CD34+CD38+
cells from FB, CB, BM, and MPB were isolated from the lineage-
depleted population (Lin−) as previously shown (Gallacher et al.,
2000). To increase efficiency, CD38 and CD33 antibodies were
added to a lineage depletion cocktail to remove CD38+ and CD33+
cells when the Lin−CD34+CD38− population was targeted for isola-
tion. Lin− cells were stained with anti-human CD34-allophyco-
cyanin (APC) and anti-human CD38-phycoerythrin (PE; Beckton
Dickinson, San Jose, CA) antibodies and sorted by fluorescence-
activated cell sorting (FACS) by using a FACSVantage SE (Beckton
Dickinson) with the sorting gates illustrated.
In Vitro and In Vivo Assays
De novo-isolated and -sorted GFP+ transgenic cells were plated in
MethoCult H4230 (Stem Cell Technologies, Vancouver, BC) to assay
for CFU potential as described previously (Murdoch et al., 2001;
2002a, 2002b). For the same experiments, unsorted cells exposed
to retrovirus were harvested from cultures and transplanted via tail
vein injection or intrafemoral bone marrow transplantation into the
femur (Mazurier et al., 2003b) of sublethally irradiated (350 cGy
137Cs) nonobese, diabetic, severe combined immune-deficient
(NOD/SCID) mice (Gallacher et al., 2000). Mice were analyzed for
human chimerism and multilineage hematopoietic composition as
shown previously (Gallacher et al., 2000; Murdoch et al., 2001). For
in vivo Brd-U incorporation, transplanted mice were administered
Brd-U (200 l, 6.25 M concentration) intraperitoneally for 3 con-
secutive days prior to analysis at 6 weeks posttransplantation of
human HSCs. HES1, HLF, and vector transgenic (GFP+) cells was
analyzed by gating on human CD45-expressing cells and/or
CD45+CD34+ cells in chimeric animals.
Ki-67 Staining
Purified cells were incubated for 30 min at 4°C in 0.4% para-formal-
dehyde with subsequent addition of 0.2% Triton X-100, followed by
overnight incubation, washing, and staining with Ki67-FITC mono-
clonal antibody (Immunotech, Burlington, Ontario) for 1 hr at 4°C.
The cycling status was analyzed by using a FACSCalibur and Cell
Quest software (Becton-Dickinson, San Jose, California).Molecular Analysis with Microarray
Total RNA was extracted and amplified as shown previously (Wang
et al., 2004) from each purified population. Amplified-labeled RNA
was hybridized to HG-U133AB chips (Affymetrix, USA) by using
standard protocols at the Ottawa Health Research Institute (OHRI;
Ottawa, Canada) and Microarray Facility of the Robarts Research
Institute (London, Ontario, Canada). The quality of the data was
assessed by examining several parameters, including the 3#:5# ra-
tio of some housekeeping genes such as β-Actin and β-Glucuroni-
dase, the percentage of present and absent calls, and background
noise. The processes of data analysis, including normalization and
clustering, were performed by using GeneSpring 6.0. The data were
normalized per array and per gene by using algorithms in Gene-
Spring 6.0. For per array normalization, data in each array were
normalized to the 50th percentile of the measurements taken from
that specific array. Per gene normalization was performed by divid-
ing the mean of the signal intensity from each gene in the selected
sample by the mean of the same gene in the control sample. Genes
that were significantly (p < 0.05) differentially (more or less than two
times) regulated in each comparison and flag present in at least
one of the experimental replicates were selected for further analy-
sis by methods used previously (Wang et al., 2004).
Conventional and Quantitative Polymerase Chain Reactions
Expression of some of the candidate genes identified in the array
analysis was quantified by quantitative real-time polymerase chain
reaction (Q-RT-PCR) (MX4000 Stratagene CA) by using SYBRGREEN
(Stratagene CA) DNA binding dye (Bustin, 2000) as previously
shown (Shojaei et al., 2004). A complete list of primers used can
be found in Table S2. The amplified products were size verified by
2% agarose gel fractionation and were also sequence verified. To
confirm that HLF-E2A rearrangements were absent in primary hu-
man cells used to create transgenic human cells, conventional PCR
was performed by using specific primers for detection of HLF-E2A
chimeric transcripts as shown previously (Devaraj et al., 1994) and
shown in Table S2.
Retroviral Gene Transfer of HES-1 and HLF into Primitive
Human Hematopoietic Cells
Primary human Lin− CB cells from four independent samples were
cultured and exposed to retrovirus as shown previously (Murdoch
et al., 2001). PA317 cells were transiently transfected with recombi-
nant HES-1 (MIEV-HES-1), HLF (MIEV-HLF), and vector alone
(MIEV) retrovirus, and viral supernatant of PA317 cells was used for
stable transduction into PG13 cells, leading to the generation of
packaging cell lines producing recombinant, HES-1, HLF, and sham
vector viral particles. CB Lin− cells were exposed to appropriate
retroviral particles by using established culture protocols (Murdoch
et al., 2001) and were harvested after 6 days of culture for subse-
quent analysis.
Staining of Cultured Cells for Brd-U, Annexin-V,
and Cell Surface Markers
The Brd-U Flow Kit (BD Pharmingen; USA) was used to analyze the
cycling status of CB Lin− cells transduced with HES1, HLF, and
vector alone. Cells were pulsed with Brd-U for 2 hr, followed by
several steps of fixation and washing according to the protocol.
The final stage included staining with anti Brd-U-APC antibody and
7-AAD to identify fractions of cells in G0/G1, S, and G2+M phases
of the cell cycle. The apoptotic status of transduced cells was eval-
uated by using the Annexin-V Apoptosis Detection Kit (BD Phar-
mingen; USA). Cells were washed with cold PBS twice and stained
with Annexin-V-PE and 7-AAD according to the protocol provided
by the manufacturer (BD Pharmingen; USA). The GFP+CD34+ pre-
apoptotic cells in each treatment were detected by gating the An-
nexin-V+7-AAD− fraction by FACSCalibur. Cell surface expression
of homing molecules was analyzed by using CD44, CD49d (VLA4),
and CXCR4 PE-conjugated antibodies (BD Pharmingen; USA).
Transgenic (GFP+) cells were gated based on coexpression of cell
surface CD34-APC, followed by evaluating expression of CD44,
CD49d, and CXCR4 as indicated.
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pStatistical analysis was performed by using T test comparison with
GraphPad Prism (GraphPad Software, Inc., San Diego, CA) or Excel G
Microsoft Software. Values were compared as means ± standard B
error of the mean, and p < 0.05 was considered statistically signifi- o
cant and is indicated by asterisks in the figures.
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CSupplemental Data detailing the full array of genes identified are
aavailable at http://www.developmentalcell.com/cgi/content/full/8/
p5/651/DC1.
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